financetom
Business
financetom
/
Business
/
Sonder Holdings Stock Spike On Heels Of Marriott Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sonder Holdings Stock Spike On Heels Of Marriott Deal
Aug 19, 2024 11:24 AM

Marriot will add Sonder's ( SOND ) portfolio of mostly apartment-style accommodations to its system under a novel collection titled "Sonder ( SOND ) by Marriott Bonvoy."Sonder Holdings, Inc. ( SOND ) shares jumped more than 125% Monday after the company announced a long-term licensing agreement with Marriott International, Inc. ( MAR ) .

What To Know: Through the licensing agreement, Marriot will add Sonder’s portfolio of mostly apartment-style accommodations to its system under a novel collection titled “Sonder by Marriott Bonvoy.”

Marriott ( MAR ) will earn a royalty fee based on a percentage of Sonder’s gross room revenues. Sonder’s rooms will gradually be integrated into Marriott’s system over several years. Additionally, Marriott ( MAR ) projects full-year 2024 net room growth to be between 6% and 6.5%.

“Marriott has long believed in providing the right product at the right price point for all trip purposes and generations of travelers. With the planned addition of Sonder ( SOND ) by Marriott Bonvoy, we will be able to provide guests seeking apartment-style urban accommodations with even more options in the Marriott Bonvoy portfolio,” said Marriott Global Officer, M&A Tim Grisius.

What Else: Sonder ( SOND ) has secured about $146 million in new liquidity, consisting of a $43 million convertible preferred equity investment from a group of investors and $83 million from existing noteholders.

The $83 million includes $4 million in recent financing. An additional $20 million comes from other sources. The aforementioned financing is in addition to a previously announced $16 million in financing from noteholders.

See Also: Wyndham Expands South Korea Presence With Trademark Debut

SOND Price Action: Sonder ( SOND ) stock is moving 125.9% higher at $5.92, according to data from Benzinga Pro.

Image: Photo via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UPS forecasts 2025 revenue below expectations, shares fall
UPS forecasts 2025 revenue below expectations, shares fall
Jan 30, 2025
(Reuters) - -United Parcel Service ( UPS ) on Thursday forecast 2025 revenue below Wall Street estimates, as gains from cost cuts were offset by customers opting for cheaper, slower ground-based deliveries from more profitable air-based services. Shares of the world's largest package delivery fell more than 5% early in the trading session. It forecast full-year revenue of $89 billion,...
Dow's Q4 Earnings, Net Sales Decline
Dow's Q4 Earnings, Net Sales Decline
Jan 30, 2025
06:14 AM EST, 01/30/2025 (MT Newswires) -- Dow (DOW) said Thursday it broke even in Q4, compared with operating earnings of $0.43 per share a year earlier. Analysts polled by FactSet expected $0.22. Net sales for the quarter ended Dec. 31 was $10.41 billion, down from $10.62 billion a year earlier. Analysts surveyed by FactSet expected $10.51 billion. ...
Cargo Therapeutics to Cut Workforce by 50%, Discontinue Lymphoma Treatment Study -- Shares Down Pre-Bell
Cargo Therapeutics to Cut Workforce by 50%, Discontinue Lymphoma Treatment Study -- Shares Down Pre-Bell
Jan 30, 2025
06:14 AM EST, 01/30/2025 (MT Newswires) -- Cargo Therapeutics ( CRGX ) said Wednesday that it will discontinue the phase 2 study of firicabtagene autoleucel, or firi-cel, for patients with large B-cell lymphoma, and reduce its workforce by about 50% to preserve cash for the development of other product candidates. The company said results from an ad-hoc analysis of the...
Thermo Fisher Scientific's Q4 Adjusted Earnings, Revenue Rise
Thermo Fisher Scientific's Q4 Adjusted Earnings, Revenue Rise
Jan 30, 2025
06:09 AM EST, 01/30/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) reported Q4 adjusted earnings Thursday of $6.10 per diluted share, up from $5.67 a year earlier. Analysts polled by FactSet expected $5.94. Revenue for the quarter ended Dec. 31 was $11.40 billion, compared with $10.89 billion a year earlier. Analysts surveyed by FactSet expected $11.28 billion. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved